Dr. Jacqueline Lui, President of Eagle IP Group, gave an in-house seminar titled “IP Due Diligence: The Key to Realistic Valuation of Technology in Transactions” at The Chamber of Hong Kong Listed Companies.
我們過去活動
Recommended Insights
Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?
2020年7月14日This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
閱讀更多 >
How to Protect a Crystal Form (Polymorph) Patent in China
2025年6月4日Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]
閱讀更多 >
New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference
2024年3月21日Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]
閱讀更多 >
Compositions Limited by Use: A Cautionary Tale
2022年10月26日Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
閱讀更多 >